Determining Worst-Case Soil in a Biopharma CDMO

We have an issue at my company where we are a Biopharma CDMO and have only 1 commericial client that we already have cleaning validation done for. We do cleaning verification for all our other clients in various phases of clinical trials. The issue with moving everything into a cleaning validation program is that we will not have toxicity data for all our APIs and likely for some of the excipients. I know we are not the only biopharma CDMO out there and I want to know how other similar organizations get around this hurdle?